secwatch.observer — SEC 8-K summary
======================================

Issuer:     CareDx, Inc. (CDNA)
CIK:        0001217234
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001217234-23-000178
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CareDx Q2 2023 revenue $70.3M (-13% YoY); net loss $0.46 per share vs $0.41 loss last year
--------------------------------------------------------------------------------

- Testing services revenue $53.4M, down 20% YoY due to Medicare Billing Article revisions.
- Patient and Digital Solutions revenue $9.0M (+33% YoY); Products revenue $7.9M (+17% YoY).
- AlloMap and AlloSure test results ~37,500 (-17% YoY); over 80% adoption of new requisition forms.
- Received first multimodal MolDX approval for HeartCare and first dd-cfDNA MolDX approval for AlloSure Lung.
- Full year 2023 revenue guidance $240M-$260M; cash and equivalents $283M, no debt.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1217234/000121723423000178/0001217234-23-000178-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1217234/000121723423000178/cdna-20230808.htm
  HTML page:      https://secwatch.observer/filing/0001217234-23-000178

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer